Close
Achema middle east
swop processing & packaging

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

Partnership will broaden portfolio distribution of oncology products to cancer patients in the specified regions

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement with CNX Therapeutics to supply selected oncology products across Central & Eastern Europe (CEE) and Türkiye.

The agreement creates an exclusive partnership for a portfolio of oncology-related medications – including CNX Therapeutics’ Cardioxane® (dexrazoxane) and Savene® (dexrazoxane) – that are part of CNX’s established oncology portfolio. Through this partnership, treatments will now be distributed across all CEE markets.

“A trusted partner and dedicated provider of oncology treatments in the region, Er-Kim has been bringing innovative oncology-related medications to emerging EMEA for 40 plus years, and we are always looking for strategic collaborations that enhance our dedication to these markets,” said Mert Zorlular, President & CFO of Er-Kim. “We are excited about our partnership with CNX Therapeutics to support the expansion of its strong portfolio of pharmaceutical options for people with cancer as we strive to improve their well-being and quality of life.”

Pete Butterfield, Chief Operating Officer at CNX Therapeutics, said, “This partnership represents a significant step forward in expanding our commercial reach. Er-Kim’s extensive regional network across Central and Eastern Europe will enable us to access new markets through their established distribution infrastructure. This is just the beginning of what we expect to be a highly successful partnership.”

Latest stories

Related stories

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »